Loading CAH detail
Loading ticker data...
Loading CAH detail
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally.
It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Chart data unavailable
CAH's specialty growth, strong pharma demand and expanding services portfolio are driving earnings momentum and positioning it for sustained long-term growth.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
FNY Investment Advisers LLC bought a new stake in shares of Cardinal Health, Inc. (NYSE: CAH) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund bought 4,000 shares of the company's stock, valued at approximately $822,000. Other hedge funds have also made changes to
CAH expands Ac-225 capacity, boosting its role in radiopharma as rising clinical demand and future cancer therapy commercialization drive growth.
CAH's specialty flywheel strategy links distribution, MSOs and biopharma services, boosting partnerships, drug launches and recurring revenue potential.
DUBLIN, Ohio, April 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced a significant expansion of its Actinium-225 (Ac-225) production capabilities at the company's Center for Theranostics Advancement (CTA) in Indianapolis, Indiana. The addition of a high-capacity production line to its Drug Master File (DMF) will substantially increase Cardinal Health's supply of cGMP-compliant Ac-225 for use in investigational therapeutic drug products and future commercial manufacturing novel therapies.
Burns Matteson Capital Management LLC lifted its position in shares of Cardinal Health, Inc. (NYSE: CAH) by 182.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,403 shares of the company's stock after buying an additional 3,492 shares during the period.
In the latest trading session, Cardinal Health (CAH) closed at $211.31, marking a +2.42% move from the previous day.
CAH's turnaround gains traction with strong earnings growth and margin expansion, outpacing MCK's steady performance outlook.
DUBLIN, Ohio, March 24, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2026 on April 30 as previously indicated, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.
CAH sees GLP-1 drugs boost revenue growth, but margins lag as strong demand lifts volumes without significantly improving profitability.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
DUBLIN, Ohio, March 23, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that its Board of Directors has appointed Patricia A. Hemingway Hall to succeed Gregory B.
Nordea Investment Management AB raised its stake in shares of Cardinal Health, Inc. (NYSE: CAH) by 328.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 645,436 shares of the company's stock after buying an additional 494,731 shares during the period. Nordea
